The sellside sees the Duchenne muscular dystrophy market as pretty much sewn up by Sarepta Therapeutics, Inc.. That group had the top three products on the market last year, and its new gene therapy, Elevidys (delandistrogene moxeparvovec), has 2028 sales forecasts of more than $3bn, Evaluate Pharma data show.
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
